Zacks Investment Research upgraded shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) from a sell rating to a hold rating in a research note released on Thursday, July 27th.
According to Zacks, “Integra exited the second quarter of 2017 on somewhat disappointing note with earnings in line with the Zacks Consensus Estimate and revenues missing the mark. We are concerned about the currency headwind that is expected to affect Integra’s financial performance in the rest of 2017. Also, contraction in adjusted operating margin and adjusted gross margin adds to the woes. On a positive note, the strong year over year increase in revenue on the back of solid performance of its Orthopedics and Tissue Technologies’ segment buoys optimism. We believe the company’s recent product diversification bolstered investors’ confidence, thereby boosting the stock price further. Overall, in the last three months, Integra Lifesciences has been consistently trading above the broader industry. However, the recent purchase of Derma Sciences and impending buyout of Codman Neurosurgery has made the stock’s valuation stretched.”
Several other equities research analysts have also weighed in on IART. Jefferies Group LLC increased their price objective on shares of Integra LifeSciences Holdings Corporation from $50.00 to $52.00 and gave the stock a buy rating in a research note on Friday, April 28th. Royal Bank Of Canada reiterated a sector perform rating and set a $48.00 price objective (up previously from $46.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Tuesday, May 2nd. Oppenheimer Holdings, Inc. set a $54.00 price objective on shares of Integra LifeSciences Holdings Corporation and gave the stock a buy rating in a research note on Monday, May 15th. ValuEngine lowered shares of Integra LifeSciences Holdings Corporation from a buy rating to a hold rating in a research note on Tuesday, May 23rd. Finally, UBS AG reiterated a buy rating and set a $60.00 price objective (up previously from $48.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Friday, June 9th. Five analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of $52.63.
Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded up 0.35% during midday trading on Thursday, hitting $49.08. The company had a trading volume of 325,548 shares. Integra LifeSciences Holdings Corporation has a 12 month low of $37.71 and a 12 month high of $56.42. The company has a market capitalization of $3.83 billion, a PE ratio of 59.85 and a beta of 0.73. The company has a 50-day moving average of $53.52 and a 200-day moving average of $46.63.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) last issued its earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.45. The business had revenue of $282.16 million for the quarter, compared to analyst estimates of $283.58 million. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The company’s revenue for the quarter was up 13.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.40 EPS. Analysts predict that Integra LifeSciences Holdings Corporation will post $1.90 earnings per share for the current year.
In other Integra LifeSciences Holdings Corporation news, Director Barbara B. Hill bought 5,050 shares of Integra LifeSciences Holdings Corporation stock in a transaction that occurred on Tuesday, August 1st. The stock was purchased at an average cost of $49.33 per share, for a total transaction of $249,116.50. Following the completion of the acquisition, the director now owns 44,772 shares of the company’s stock, valued at approximately $2,208,602.76. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Stuart Essig sold 135,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $49.90, for a total transaction of $6,736,500.00. Following the sale, the director now owns 2,077,475 shares of the company’s stock, valued at $103,666,002.50. The disclosure for this sale can be found here. Insiders bought 17,550 shares of company stock valued at $864,842 over the last quarter. Insiders own 21.50% of the company’s stock.
A number of hedge funds have recently modified their holdings of the company. LS Investment Advisors LLC boosted its stake in shares of Integra LifeSciences Holdings Corporation by 4.6% in the second quarter. LS Investment Advisors LLC now owns 2,523 shares of the life sciences company’s stock worth $138,000 after buying an additional 111 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in shares of Integra LifeSciences Holdings Corporation by 1.2% in the second quarter. Louisiana State Employees Retirement System now owns 24,600 shares of the life sciences company’s stock worth $1,341,000 after buying an additional 300 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of Integra LifeSciences Holdings Corporation by 1.3% in the second quarter. Arizona State Retirement System now owns 31,594 shares of the life sciences company’s stock worth $1,722,000 after buying an additional 400 shares during the last quarter. US Bancorp DE boosted its stake in shares of Integra LifeSciences Holdings Corporation by 2.6% in the second quarter. US Bancorp DE now owns 23,620 shares of the life sciences company’s stock worth $1,288,000 after buying an additional 593 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Integra LifeSciences Holdings Corporation by 77.7% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,697 shares of the life sciences company’s stock worth $100,000 after buying an additional 742 shares during the last quarter. Hedge funds and other institutional investors own 89.56% of the company’s stock.
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Get a free copy of the Zacks research report on Integra LifeSciences Holdings Corporation (IART)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
